Antibe Therapeutics - Working towards a GI-safe NSAID drug
Antibe’s lead drug, ATB-346, combines a hydrogen sulfide (H2S)-emitting molecule with naproxen, an off-patent non-steroidal anti-inflammatory drug (NSAID). The firm plans to start a double-blinded Phase IIb osteoarthritis (OA) study in July 2018, with data expected in Q418. The trial’s efficacy results can build on recent Phase IIb gastrointestinal (GI) safety data and position Antibe well to seek ATB-346 partnerships or out-licensing deals.Antibe Therapeutics originates, develops and out-licenses patent-protected new pharmaceuticals that are improved versions of existing drugs. Co.'s lead compound, ATB-346, combines hydrogen sulfide with naproxen, an approved, marketed and off-patent non-steroidal anti-inflammatory drug. Co.'s main objective is to develop ATB-346 to the end of Phase II, a possible strategic exit point, by satisfying the requirements of both the drug regulatory authorities and potential commercial licensors and global partners.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.